News und Analysen
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
EQS-News: Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets